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1. Introduction
  The green fluorescent protein (GFP) is a kind of monomer 
photoprotein that is composed of 238 amino acids and 
has molecular weight of 27-30 Kd[1-4]. It can undergo 
autocatalysis to form chromophore without any cofactors, 
showing green fluorescence once it is excited by near-
ultraviolet or blue light. The enhanced green fluorescent 
protein (EGFP) has been produced by replacing Thr and 
Leu with Ser65 and Phe64, respectively, and it shows 
enhanced fluorescence strength by around 35 times when 
compared with GFP, and also exhibits improved sensitivity 
for reporter gene[5]. Therefore, EGFP has been widely 
used in the biomedical field as a multi-functional tool 
for some qualitative or quantitative investigations such 
as protein interaction, enzymatic activities, drug monitor, 
gene expression, protein localization, evaluation on the 
therapeutic effects of tumor vaccines, fluorescence labeling 
of targeted proteins and so on[6-17]. But it is still unclear 
whether its fluorescence intensity would be changed or not 
when it is fused with some exogenous genes.
Objective: To investigate the effect of fusion proteins expressed by the fused gene of porcine 毩1,3 
galactosyltransferase (毩1,3 GT) and enhanced green fluorescent protein (EGFP) on the green 
fluorescence intensity of EGFP. Methods: The fragment containing 毩1,3GT was firstly recovered 
after the pcDNA3.1-毩1,3GT recombinant vector were digested with BamHI and EcoRI, and 
then, the resultant fragment was ligated to the pEGFP-N1 vector which was also digested with 
the same enzymes. The new recombinant eukaryotic expression pEGFP/毩1,3GT vector was 
obtained and sequenced. The pEGFP/毩1,3GT was used to transfect human lung carcinoma cells 
A549 and HEKC 293FT, and the expression of EGFP was quantitatively analyzed by fluorescent 
microscope and flow cytometry. Results: The positive percentage of A549 was 80.5%, and that 
of 293 FT was 86.5% 48 hours after the two cell lines both were transfected by pEGFP-N1. The 
positive percentage of A549 was 75.8%, and that of 293 FT was 81.2% 48 hours after the two cell 
lines were transfected by pEGFP/毩1,3GT. The mean fluorescence intensities of A549 transfected 
with pEGFP-N1 and pEGFP/毩1,3GT were 1.21 and 0.956, respectively when compared with that of 
A549 without transfection. Meanwhile, the those of the 293FT that were transfected with pEGFP-
N1 and pEGFP/毩1,3GT were 7.66 and 1.00, respectively when compared with that of 293FT cells 
without transfection. Conclusions: These results suggested that the expression of EGFP gene 
fused with porcine 毩1,3GT gene was partly inhibited.
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  Gal毩1-3Gal毬1-(3)4GlcNAc-R, i.e., 毩Gal antigen, is a 
glycoprotein that is catalyzed and synthesized by毩1,3GT on 
the cell surface of all non-primate mammals except for the 
old century primates and human. Gal毩(1,3)Gal antigen is 
not expressed in old century primates and human since it is 
depleted or replaced by a pseudogene during the evolution 
of 毩1,3GT gene[18,19]. However, old century primates and 
human can produce the natural antibody to Gal epitope 
after their birth as a result of the immune responses to 
gastrointestinal bacterial flora and other pathogens that 
carry the Gal毩(1,3)Gal saccharide group structures[20]. 
During xeno-transplantation, such as the transplantation of 
organs from pigs into human bodies, the anti-Gal antibody 
can bind to the 毩Gal antigen on the surface of vascular 
endothelial cells of pigs and thus induce the hyperacute 
rejection, and finally lead to the deactivation and cellular 
necrosis of the grafts[21-24]. On the basis of the hyperacute 
rejection mechanism, we attempted to express the porcine 
毩Gal antigen in human tumor cells or/and tumor vascular 
endothelial cells by the transfection of these cells with the 
fusion gene of porcine 毩1,3GT and EGFP, and thus the anti-
tumor effects can be realized by the hyperacute rejection 
that was induced by the 毩Gal antigen binding to the natural 
anti-Gal antibody in the human body, with an objective to 
observe the production process of the fusion protein under 
the fluorescent microscope and understand the in vivo 
expression of the target gene in the near future, and finally 
realize the efficient monitoring and analysis on the effects of 
targeted killing of tumor cells by using the target gene 毩1,3GT. 
  This investigation tried to understand the effect of fusion 
of porcine 毩1,3GT and EGFP genes on the expression of 
the green fluorescent protein in order to establish the basis 
for the evaluations on the therapeutic effects of anti-tumor 
vaccine by using porcine 毩1,3GT gene. 
2. Materials and methods
2.1. Plasmids and strains
  Porcine gene 毩1,3GT and pCDNA3.1/毩1,3GT gene were 
constructed previously in our laboratory. pEGFP-N1 
(CLONTECH Laboratories, Inc. Mountain View, CA, U.S.A.) 
contains CMV promoter and EGFP gene. DH5毩 strain was 
purchased from Invitrogen (Carlsbad, CA, U.S.A.). 
2.2. Cell lines
  A549 (American Type Tissue Culture Collection, Manassas, 
VA, U.S.A.) and 293FT (Invitrogen Life Technologies, CA, 
U.S.A.) were maintained in DMEM media (Invitrogen, 
Carlsbad, CA, USA) supplemented with 10% fetal calf serum 
(FCS, HyClone, Logan, USA) and antibiotics.
2.3. Reagents
  Lipofectimine 2000 transfection reagents were purchased 
from Invitrogen (Carlsbad, CA, USA). Plasmid miniprep kit, 
ligation kit, restriction enzymes BamHI and EcoRI, recovery 
and purification reagents for target gene were purchased 
from Takara Company (Osaka, Japan).
2.4. Construction of pEGFP/毩1,3GT eukaryotic expression 
vector
  pEGFP-N1 and pCDNA3.1/毩1,3GT both were digested with 
BamHI and EcoRI, and 1 050 bp target fragment of 毩1,3GT 
was recovered. The fragment was then ligated to the pEGFP-
N1 vector at 16 曟 for 3 h. Ten 毺L ligation product was 
used to transform DH5毩, subsequently the recombinant 
plasmid was extracted and subjected to enzymatic digestion 
identification, and finally, the eukaryotic expression 
vector containing EGFP was constructed (Figure 1). The 
recombinant plasmid was verified with DNA sequencing.
BamH1 & EcoR1 digest                                          BamH1 & EcoR1 digest
Alpha毩1, 3GT
Ligase ligation
CMV
pc(DNA3,1-alphal,
3GT  5 750 bp
alpha 1,3,GT
EcoRI
BamHI
CMV
EcoRI
BamHI
FGFP
CMV
EcoRI
MCS
BamHI
FGFP
Ampicillin
CMV
pc(DNA3,1-alphal,
3GT  6 478 bp
alpha 1,3,GT
EcoRI
BamHI
EGFP
Kan
Figure 1.  The vector for fusion of EGFP and porcine 毩1,3GT genes.
2.5. Transfection of A549 and 293FT cells
  A549 and 293FT cells were inoculated in two six-well plates 
and cultured overnight in order to reach a cell-fusion rate 
between 80%-90%. The blank control groups (which were 
not transfected), the experimental control groups (which 
were transfected with pEGFP-N1) and the experimental 
groups (which were transfected with pEGFP/毩1,3GT) were 
established, and the cells were transfected by using the 
liposome method in which about 4.0 毺g plasmid and 10 毺L 
liposome were added into the six-well plates.
2.6.Detection of EGFP expression by the fluorescent microscope
  The expression of EGFP was observed by using the 
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fluorescent microscope after the transfection of the A549 
and 293FT cells for 24, 48 and 72 h, respectively. To quantify 
the expression of EGFP, the number of positive cells was 
counted in 10 random fields per well.
2.7. Detection of EGFP expression by the flow cytometry
  A549 and 293FT cells were rinsed twice with PBS for 48 h 
after the transfection, subsequently they were digested 
with trypsin and prepared into cell suspension with PBS 
and then filtered with a copper screen of 200 meshes. The 
samples were analyzed by FACScalibur (Becton Dickinson, 
Heidelberg, Germany).
3. Results
3.1. Verification of pEGFP/毩1,3GT recombinant plasmid
  The recombinant plasmid was verified with restriction 
enzyme analysis and DNA sequencing. The plasmid was 
digested by BamHI and EcoRI, digests were analyzed 
with 1% agarose gel electrophoresis (data not shown). Both 
the digested fragments and DNA sequence analysis (data 
not shown) indicated that the recombinant plasmid was 
constructed correctly.
3.2.The expression and localization of pEGFP-N1 and pEGFP/
毩1,3GT 
  The positive rates for the transfection of A549 and 293FT 
cells with pEGFP-N1 vector after 48 h were 80.5% and 86.5%, 
respectively, and the transfection efficiency of A549 and 
293FT cells with pEGFP/毩1,3GT after 48 h were 75.8% and 
81.2%, respectively. The number of fluorescent cells and 
the fluorescence intensities of pEGFP/毩1,3GT transfection 
groups were significantly lower than those of pEGFP-N1 
groups, while no fluorescence was found in the blank control 
groups (Figure 2). The localization of the fusion protein was 
observed under laser scanning confocal microscope 48 h 
after the transfection (Figure 3). 
A549
293FT
Figure 2. Expression and localization of pEGFP-N1 and pEGFP/毩1,3GT.
A: A549 cell lines. B: 293FT cell lines. A1(伊200) and B1(伊200) 
are the blank controls. A2 (伊200) and B2 (伊200) are transfected by 
pEGFP-N1. A3 (伊200) and B3 (伊200) are transfected by pEGFP/毩
1,3GT. Arrows indicated the signals for the expression of EGFP.
DAP1
EGFP
MERGE
Figure 3. The transfection of A549 cell lines. 
A: the blank control. B: pEGFP-N1 transfection. C: pEGFP-毩1,3GT 
transfection. Arrows indicated the localization for the expression 
of EGFP. All of the figures were captured under the laser scanning 
confocal microscope (伊1600).
3.3. The flow cytometry analysis of the fluorescence intensity 
  As shown in Figure 4, the mean fluorescence intensity of 
A549 cells that were transfected by pEGFP-N1 and pEGFP/毩1,3GT 
was 1.21 and 0.956, respectively, and the mean fluorescence 
intensity of 293FT cells that were transfected with pEGFP-
N1 and pEGFP/毩1,3GT was 7.66 and 1.00, respectively. 
The fluorescence expression intensities of pEGFP-N1 
and pEGFP/毩1,3GT groups were significantly higher than 
those of the blank control groups, whereas the fluorescence 
expression intensities of the pEGFP/毩1,3GT groups were 
significantly lower than those of the pEGFP-N1 groups 
(Figure 4).  
4. Discussion
  Reporter genes have been used in the investigations on 
gene therapy[25,26]. The advantages of EGFP are as follows: 
high fluorescence intensity, easily observation under 
common fluorescent microscopes, no requirements for 
substrates and cofactors, liable fusion by using relatively 
small molecules and monomer protein, and no effects 
on activities of normal cells. However, the study for its 
fluorescent intensity stabilization has not been reported so 
far after EGFP gene is fused with exogenous genes.
  The present study found fluorescence intensity of pEGFP/
毩1,3GT was significantly lower than that of the pEGFP-N1 in 
the transfection of A549 or 293FT cells that were transfected 
with recombinant plasmid pEGFP/毩1,3GT. The reasons may 
be that the 毩1,3GT gene was inserted into the C-terminus 
of pEGFP-N1 and the molecular weight of fusion protein was 
heavier than that of a single EGFP protein, which may affect 
the formation of green fluorescence chromophore in the 
spatial structure of protein conformation. On the other hand, 
fluorescence intensity was also related to the transfection 
conditions of cell lines. This investigation also found that the 
fluorescence intensity was different although the cell lines 
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A549 and 293FT were transfected with the same plasmid, but 
the expression intensity of pEGFP-N1 before the fusion was 
significantly higher than that of the pEGFP/毩1,3GT after the 
recombination. These results reveal that further reformation 
need performing on EGFP in order to improve the expression 
level of the recombinant green fluorescent protein, while 
the method for the fusion protein synthesis by genetic 
engineering and stability for the fusion protein expression 
still need to be further improved. Therefore, the following 
points should be minded when green fluorescent fusion 
proteins containing target genes are used for the evaluations 
on the therapeutic effects of antitumor tracing. The first one 
is that the green fluorescence intensity may be reduced after 
exogenous genes are introduced into target cells, which may 
lead to certain influence on the expression and localization 
of target genes. The second one is whether the expression 
of green fluorescent fusion protein will affect the functional 
expression of target proteins. Investigations from Huang et 
al on ZZ-EGFP fusion protein indicated that the expression 
of fusion protein did not significantly affect the expression 
of target gene and the ZZ-EGFP fusion protein can retain 
all expected characteristics (extremely high solubility and 
relatively high yield)[27], which was in accordance to the 
results in the present study (the experimental data will be 
published in another manuscript). The third one is whether 
EGFP shows toxicity to cells. The poor status of cells may 
directly affect the transfection efficiency if EGFP shows 
toxicity to cells, which may inevitably lead to the decrease 
in the expression level of green fluorescent fusion protein. 
Alexander et al cloned the target gene fragment into pEGFP-
C1 vector and constructed a recombinant plasmid, and they 
discovered that EGFP did not show toxicity to cells[28, 29], which 
was similar to our current results. However, Liu et al found 
that NIH/3T3 and BHK-21 cell lines underwent apoptosis 
shortly after the transfection with EGFP, which may be 
related to the different tolerance of cells[30].
  The treatment of tumors with target genes is a kind 
of theoretically effective method[31], but substantial 
improvements are still needed for practical operation 
process. With the developments in investigations on the 
mechanisms of fusion protein formation, variations and 
mutations during the synthesis process of fusion genes 
and the introduction of cofactors, it is believed that 
breakthroughs in the gene therapy on tumors are inevitably 
achieved. 
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Figure 4.  Flow cytometry analysis of the fluorescence intensity. 
Group A: A549 cell lines, Group B: 293FT cell lines. A1 and B1 were the blank controls and the mean fluorescence intensity of them was 0.577 
and 0.516, respectively. The mean fluorescence intensities of A2 and B2 transfected with pEGFP-N1 were 1.21 and 7.66, respectively. The 
mean fluorescence intensities of A3 and B3 transfected with pEGFP-毩1,3GT were 0.956 and 1.000, respectively.
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